title: Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo.
abstract: Monoterpenes are prescribed to treat chronic obstructive airway disorders mainly because of their familiar secretolytic properties. The aim of this study was to investigate the effect of 1.8-cineole (Soledum) on arachidonic acid (AA) metabolism in blood monocytes of patients with bronchial asthma. Patients with bronchial asthma (n = 10) and healthy test subjects (n = 12) were included in the study. Production of the representative AA-metabolites LTB4 and PGE2 from isolated monocytes stimulated with the calcium ionophore A23187 were measured ex vivo before therapy with 1.8-cineole (3 x 200 mg/day), after three days of treatment (day 4) and four days after discontinuation of 1. 8-cineole (day 8). The production of LTB4 and PGE2 from monocytes ex vivo was significantly inhibited on day 4 in patients with bronchial asthma (-40.3%, n = 10 and -31.3%, p = 0.1, n = 3 respectively) as well as in healthy volunteers (-57.9%, n = 12 and -42.7%, n = 8 respectively). In conclusion, 1.8-cineole was shown to inhibit LTB4 and PGE2, both pathways of AA-metabolism. Further studies are needed to show that 1.8-cineole is suitable in the treatment of bronchial asthma.
authors.affiliation: Abteilung Pneumologie, Medizinische Universitäts-Poliklinik Bonn, Wilhelmstrasse 35-37, D-53111 Bonn, Germany. EurJMedRes@t-online.de
authors.forename: U R
authors.initials: UR
authors.lastname: Juergens
authors.forename: M
authors.initials: M
authors.lastname: Stöber
authors.forename: L
authors.initials: L
authors.lastname: Schmidt-Schilling
authors.forename: T
authors.initials: T
authors.lastname: Kleuver
authors.forename: H
authors.initials: H
authors.lastname: Vetter
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000001:Calcimycin / Q000494:pharmacology; D003511:Cyclohexanols; D000077591:Eucalyptol; D005541:Forced Expiratory Volume; D006801:Humans; D018836:Inflammation Mediators; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D008610:Menthol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D039821:Monoterpenes; D013729:Terpenes
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003511:Cyclohexanols; D018836:Inflammation Mediators; D007375:Interleukin-1; D039821:Monoterpenes; D013729:Terpenes; D008610:Menthol; D007975:Leukotriene B4; D016718:Arachidonic Acid; D000001:Calcimycin; D000077591:Eucalyptol